HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
S0115 | Bortezomib | Velcade | 3.5 mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2003 | Jan 1, 2004 | Dec 31, 2004 | No Longer Used | |
NA | Bosutinib | Bosulif | 500 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
J9080 | Cyclophosphamide | Cyclophosphamide | 200 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 0.625 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
Q5120 | Pegfilgratim-bmez | Ziextenzo | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony Stimulating Factor | No | 2019 | Jul 1, 2020 | In Use | ||
Q5127 | Pegflilgrastim-fpgk | Stimufend | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | Mar 17, 2023 | In Use | ||
J3120 | Testosterone Enanthate | Testosterone Enanthate | 100 mg | Hormonal Therapy | Androgen | No | 1953 | Jan 1, 1982 | Jan 1, 2015 | No Longer Used | ||
C9257 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jan 1, 2010 | In Use | ||
J9265 | Paclitaxel | Taxol | 30 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1992 | Jan 1, 1994 | Dec 31, 2014 | No Longer Used | |
NA | Pazopanib | Votrient | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT, Lck, FMS | Yes | 2009 | In Use | |||
J9098 | Cytarabine | Cytarabine Liposome | 10 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1999 | Jan 1, 2004 | In Use | ||
NA | Glasdegib | Daurismo | 25mg, 100mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2018 | In Use | |||
NA | Metoclopramide | Reglan | 5mg, 10mg | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Yes | 1991 | In Use | |||
Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
C9210 | Palonosetron | Aloxi | 25 mcg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 2003 | Jan 1, 2004 | Dec 31, 2004 | No Longer Used | |
NA | Cyclosporine | Gengraf | 25mg, 50mg, 100mg | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Yes | 2010 | In Use | |||
NA | Rucaparib | Rubraca | 200 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | idelalisib | Zydelig | 150 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
NA | Pomalidomide | Pomalyst | 2 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
C9422 | Cytarabine | Cytarabine | 100 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1998 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
J9140 | Dacarbazine | Dacarbazine | 200 mg | Chemotherapy | Alkylating Agent | Purine Analog | No | 1975 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
C9292 | Pertuzumab | Perjeta | 10 mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2012 | Oct 1, 2012 | Dec 31, 2013 | No Longer Used | |
J9316 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf | Phesgo | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2020 | Jan 1, 2021 | In Use | ||
NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
J9049 | Bortezomib (Hospira) | Bortezomib (Hospira) | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2022 | Dec 21, 2022 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.